Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - zonisamide - capsule, hard - 50 milligram(s) - other antiepileptics; zonisamide

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - zonisamide - capsule, hard - 100 milligram(s) - other antiepileptics; zonisamide

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

bryant ranch prepack - zonisamide (unii: 459384h98v) (zonisamide - unii:459384h98v) - zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonisamide capsules are contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide. the abuse and dependence potential of zonisamide has not been evaluated in human studies (see warnings, cognitive/neuropsychiatric adverse events subsection). in a series of animal studies, zonisamide did not demonstrate abuse liability and dependence potential. monkeys did not self-administer zonisamide in a standard reinforcing paradigm. rats exposed to zonisamide did not exhibit signs of physical dependence of the cns-depressant type. rats did not generalize the effects of diazepam to zonisamide in a standard discrimination paradigm after training, suggesting that zonisamide does not have abuse potential of the benzodiazepine-cns depressant type.

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

mylan pharmaceuticals limited - zonisamide - epilepsy - antiepileptics, - monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

bryant ranch prepack - zonisamide (unii: 459384h98v) (zonisamide - unii:459384h98v) - zonisamide is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonisamide is contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide. the abuse and dependence potential of zonisamide has not been evaluated in human studies (see warnings, cognitive/neuropsychiatric adverse events subsection). in a series of animal studies, zonisamide did not demonstrate abuse liability and dependence potential. monkeys did not self-administer zonisamide in a standard reinforcing paradigm. rats exposed to zonisamide did not exhibit signs of physical dependence of the cns-depressant type. rats did not generalize the effects of diazepam to zonisamide in a standard discrimination paradigm after training, suggesting that zonisamide does not have abuse potential of the benzodiazepine-cns depressant type.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

bryant ranch prepack - zonisamide (unii: 459384h98v) (zonisamide - unii:459384h98v) - zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonisamide capsules are contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - zonisamide, quantity: 50 mg - capsule, hard - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; hydrogenated vegetable oil; sodium lauryl sulfate; titanium dioxide; purified water; gelatin; iron oxide black - zonisamide is indicated as:,- monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy who are intolerant to other agents or where other agents are contraindicated;,- adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - zonisamide, quantity: 100 mg - capsule, hard - excipient ingredients: sodium lauryl sulfate; colloidal anhydrous silica; microcrystalline cellulose; hydrogenated vegetable oil; titanium dioxide; sunset yellow fcf; purified water; allura red ac; gelatin - zonisamide is indicated as:,- monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy who are intolerant to other agents or where other agents are contraindicated;,- adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - zonisamide, quantity: 25 mg - capsule, hard - excipient ingredients: hydrogenated vegetable oil; sodium lauryl sulfate; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; purified water; gelatin - zonisamide is indicated as:,- monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy who are intolerant to other agents or where other agents are contraindicated;,- adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - zonisamide - capsule, hard - 100 milligram(s) - other antiepileptics; zonisamide